Knockdown of OCT4 may sensitize NSCLC cells to cisplatin.

about

Overexpression of miR-216b sensitizes NSCLC cells to cisplatin-induced apoptosis by targeting c-Jun.

P2860

Q47143327-2CAD149D-9AF0-4D66-A3AD-2A1CBAB9130C

P2860

Knockdown of OCT4 may sensitize NSCLC cells to cisplatin.

Item

http://www.wikidata.org/entity/Q38731917

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Knockdown of OCT4 may sensitize NSCLC cells to cisplatin.

@en

type

Item

label

Knockdown of OCT4 may sensitize NSCLC cells to cisplatin.

@en

prefLabel

Knockdown of OCT4 may sensitize NSCLC cells to cisplatin.

@en

P1476

Knockdown of OCT4 may sensitize NSCLC cells to cisplatin.

@en

P2093

H Zhang

http://www.w3.org/2001/XMLSchema#string

M Ma

http://www.w3.org/2001/XMLSchema#string

M Yang

http://www.w3.org/2001/XMLSchema#string

X Duan

http://www.w3.org/2001/XMLSchema#string

X Liu

http://www.w3.org/2001/XMLSchema#string

P2860

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Oct-4 expression maintained cancer stem-like properties in lung cancer-derived CD133-positive cells

Targeting multidrug resistance in cancer

Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.

Expression of Sox2 and Oct4 and their clinical significance in human non-small-cell lung cancer.

Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403).

Downregulation of KPNA2 in non-small-cell lung cancer is associated with Oct4 expression

Second line treatments in advanced platinum-resistant non small cell lung cancer. A critical review of literature.

Over-expression of Nanog predicts tumor progression and poor prognosis in colorectal cancer.

Direct reprogramming of human neural stem cells by OCT4.

P2888

s12094-016-1569-y

P304

587-592

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12094-016-1569-Y

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-11-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27832473

http://www.w3.org/2001/XMLSchema#string

Knockdown of OCT4 may sensitize NSCLC cells to cisplatin.

about

P2860

P2860

Knockdown of OCT4 may sensitize NSCLC cells to cisplatin.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P698